The Nocebo Effect Across Therapeutic Conditions: Implications for Pharmacy Counselling

The nocebo effect describes adverse symptoms, treatment experiences, or treatment-related concerns that arise or become amplified through negative expectations, prior learning, contextual cues, anxiety, and interpretation of bodily sensations. Although the symptoms are experienced as real, their occurrence may not be explained solely by the pharmacological action of a medicine. This review integrates ten supplied references addressing the nocebo phenomenon across gastrointestinal disorders, inflammatory bowel disease, psychotropic treatment, statin therapy, pain, oncology, endometriosis, neurology, immunology, and broader healthcare communication. Evidence from randomized trials, clinical reviews, adverse-event reporting, and communication-focused literature indicates that nocebo responses can increase symptom reporting, treatment withdrawal, anxiety, pain amplification, and perceived treatment intolerance. In neuromodulator trials for disorders of gut– brain interaction, adverse events and withdrawals were also observed in placebo groups, while in other settings contextual factors and expectations influenced the pattern of symptoms reported. Proposed mechanisms include negative expectancy and conditioning, activation of cholecystokinin-related pathways, modulation of endogenous opioid and dopaminergic signalling, hypothalamic–pituitary–adrenal axis activation, cortisol responses, and autonomic changes. The clinical challenge is particularly important for pharmacy practice because counselling is a modifiable component of the treatment environment. Pharmacists must communicate risks sufficiently for informed decision-making while avoiding unnecessarily alarming or decontextualized descriptions that may intensify fear and symptom vigilance. A patient centred approach should therefore explore beliefs and previous experiences, explain expected benefits, distinguish common manageable effects from serious warning signs, validate symptoms without premature attribution, encourage appropriate reporting, and support shared decisionmaking. Future research should evaluate pharmacist-led communication strategies using standardized nocebo outcomes, adherence measures, and patient-reported experiences across therapeutic areas